Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday announced an agreement with the University of California ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

In an analysis of 1,034 fit adults aged 70 years and younger, age and genetic features were identified as the factors most ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Researchers from Karl Landsteiner University of Health Sciences (KL Krems) have discovered that combining two existing drugs ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is excited to announce its ...